Ankit Bharat Patel, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetic Nephropathies | 3 | 2021 | 984 | 1.040 |
Why?
|
Hypophosphatemia, Familial | 1 | 2020 | 34 | 0.750 |
Why?
|
Sodium-Phosphate Cotransporter Proteins, Type IIa | 1 | 2020 | 44 | 0.750 |
Why?
|
Feedback, Physiological | 2 | 2014 | 479 | 0.750 |
Why?
|
Naphthyridines | 1 | 2021 | 118 | 0.740 |
Why?
|
Sodium | 4 | 2014 | 1623 | 0.700 |
Why?
|
Immunoglobulin kappa-Chains | 1 | 2019 | 173 | 0.690 |
Why?
|
Nephrolithiasis | 1 | 2020 | 110 | 0.670 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3133 | 0.630 |
Why?
|
Coronavirus | 1 | 2020 | 158 | 0.630 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3240 | 0.620 |
Why?
|
Angiotensin Receptor Antagonists | 2 | 2021 | 924 | 0.610 |
Why?
|
Kidney Tubules, Proximal | 1 | 2019 | 416 | 0.610 |
Why?
|
Nephrology | 3 | 2019 | 263 | 0.570 |
Why?
|
Podocytes | 1 | 2019 | 396 | 0.530 |
Why?
|
Peptidyl-Dipeptidase A | 3 | 2020 | 365 | 0.480 |
Why?
|
Career Choice | 3 | 2019 | 744 | 0.480 |
Why?
|
Pandemics | 5 | 2020 | 8388 | 0.460 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 1518 | 0.450 |
Why?
|
Tissue Kallikreins | 1 | 2012 | 15 | 0.430 |
Why?
|
Renal Insufficiency, Chronic | 3 | 2023 | 2208 | 0.410 |
Why?
|
Antihypertensive Agents | 1 | 2020 | 2046 | 0.370 |
Why?
|
Diabetes Mellitus, Type 2 | 4 | 2021 | 11725 | 0.360 |
Why?
|
Enzyme Inhibitors | 1 | 2021 | 3798 | 0.360 |
Why?
|
Education, Medical, Undergraduate | 2 | 2019 | 1008 | 0.330 |
Why?
|
Antiviral Agents | 1 | 2021 | 2987 | 0.320 |
Why?
|
Kidney Diseases | 1 | 2019 | 2149 | 0.320 |
Why?
|
Students, Medical | 2 | 2019 | 1862 | 0.250 |
Why?
|
Education, Medical | 1 | 2013 | 1721 | 0.190 |
Why?
|
Hypertension | 2 | 2020 | 8480 | 0.190 |
Why?
|
Algorithms | 1 | 2020 | 13881 | 0.180 |
Why?
|
Receptors, Mineralocorticoid | 1 | 2021 | 164 | 0.180 |
Why?
|
Ureter | 1 | 2022 | 375 | 0.180 |
Why?
|
Angiotensins | 1 | 2020 | 151 | 0.180 |
Why?
|
Models, Immunological | 1 | 2022 | 527 | 0.170 |
Why?
|
Phosphorus | 1 | 2020 | 338 | 0.170 |
Why?
|
Republic of Korea | 1 | 2020 | 539 | 0.160 |
Why?
|
Crystallization | 1 | 2019 | 524 | 0.160 |
Why?
|
Hypokalemia | 1 | 2019 | 153 | 0.160 |
Why?
|
Resuscitation | 1 | 2023 | 658 | 0.160 |
Why?
|
Horner Syndrome | 1 | 2018 | 37 | 0.160 |
Why?
|
Creatinine | 2 | 2023 | 1919 | 0.160 |
Why?
|
Oocytes | 2 | 2014 | 1187 | 0.150 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2019 | 712 | 0.150 |
Why?
|
Hyponatremia | 1 | 2020 | 298 | 0.150 |
Why?
|
Clinical Competence | 1 | 2013 | 4687 | 0.150 |
Why?
|
Jugular Veins | 1 | 2018 | 204 | 0.150 |
Why?
|
Acute Kidney Injury | 2 | 2020 | 1972 | 0.150 |
Why?
|
Paraproteinemias | 1 | 2019 | 246 | 0.150 |
Why?
|
Virus Internalization | 1 | 2020 | 501 | 0.140 |
Why?
|
Renin-Angiotensin System | 1 | 2020 | 759 | 0.140 |
Why?
|
Vasodilation | 1 | 2020 | 944 | 0.140 |
Why?
|
Albuminuria | 1 | 2019 | 682 | 0.130 |
Why?
|
Pluripotent Stem Cells | 1 | 2022 | 795 | 0.130 |
Why?
|
Lung Injury | 1 | 2020 | 436 | 0.130 |
Why?
|
Diuretics | 2 | 2020 | 592 | 0.120 |
Why?
|
Humans | 28 | 2023 | 744343 | 0.120 |
Why?
|
Cyclophosphamide | 1 | 2019 | 2242 | 0.120 |
Why?
|
Receptors, Immunologic | 1 | 2020 | 1423 | 0.110 |
Why?
|
Catheterization, Central Venous | 1 | 2018 | 514 | 0.110 |
Why?
|
Amiloride | 1 | 2012 | 121 | 0.110 |
Why?
|
Liver Cirrhosis | 1 | 2023 | 1863 | 0.110 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2012 | 226 | 0.110 |
Why?
|
Dexamethasone | 1 | 2019 | 1951 | 0.110 |
Why?
|
Xenopus | 1 | 2014 | 712 | 0.100 |
Why?
|
Water-Electrolyte Balance | 1 | 2012 | 346 | 0.100 |
Why?
|
Rats, Sprague-Dawley | 2 | 2012 | 8301 | 0.100 |
Why?
|
Glomerular Filtration Rate | 2 | 2023 | 2170 | 0.100 |
Why?
|
Ischemia | 1 | 2020 | 1907 | 0.090 |
Why?
|
Aldosterone | 2 | 2012 | 877 | 0.090 |
Why?
|
Faculty, Medical | 1 | 2018 | 1181 | 0.090 |
Why?
|
Anti-Inflammatory Agents | 1 | 2019 | 1790 | 0.090 |
Why?
|
Drug Therapy, Combination | 1 | 2019 | 6489 | 0.090 |
Why?
|
Thrombolytic Therapy | 1 | 2018 | 2161 | 0.080 |
Why?
|
Clinical Trials as Topic | 2 | 2022 | 7913 | 0.080 |
Why?
|
Fibrinolytic Agents | 1 | 2018 | 2158 | 0.080 |
Why?
|
Xenopus laevis | 1 | 2012 | 957 | 0.080 |
Why?
|
Structure-Activity Relationship | 1 | 2014 | 3129 | 0.080 |
Why?
|
Potassium | 1 | 2012 | 1336 | 0.080 |
Why?
|
Nerve Tissue Proteins | 1 | 2020 | 4462 | 0.070 |
Why?
|
Immunosuppressive Agents | 1 | 2019 | 4149 | 0.070 |
Why?
|
Water | 1 | 2012 | 1395 | 0.070 |
Why?
|
Educational Measurement | 1 | 2013 | 1210 | 0.070 |
Why?
|
Rats | 2 | 2012 | 24260 | 0.070 |
Why?
|
Gene Expression Regulation | 3 | 2012 | 12072 | 0.070 |
Why?
|
Pulmonary Embolism | 1 | 2018 | 2376 | 0.060 |
Why?
|
Animals | 7 | 2020 | 168757 | 0.060 |
Why?
|
Tenebrio | 1 | 2004 | 2 | 0.060 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3229 | 0.060 |
Why?
|
Malpighian Tubules | 1 | 2004 | 9 | 0.060 |
Why?
|
Insect Hormones | 1 | 2004 | 75 | 0.060 |
Why?
|
Diuresis | 1 | 2004 | 116 | 0.060 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 12959 | 0.060 |
Why?
|
Kidney | 4 | 2023 | 7186 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 9959 | 0.060 |
Why?
|
MicroRNAs | 1 | 2020 | 3752 | 0.060 |
Why?
|
Aedes | 1 | 2004 | 100 | 0.060 |
Why?
|
Social Support | 1 | 2013 | 2118 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2014 | 10943 | 0.060 |
Why?
|
Cyclic GMP | 1 | 2004 | 409 | 0.060 |
Why?
|
Body Fluids | 1 | 2004 | 319 | 0.050 |
Why?
|
Cystatin C | 1 | 2023 | 250 | 0.050 |
Why?
|
Mice | 3 | 2020 | 81183 | 0.050 |
Why?
|
Amino Acid Sequence | 1 | 2012 | 13815 | 0.040 |
Why?
|
Prognosis | 1 | 2020 | 29063 | 0.040 |
Why?
|
Osmolar Concentration | 1 | 2020 | 683 | 0.040 |
Why?
|
Molecular Sequence Data | 1 | 2012 | 18111 | 0.040 |
Why?
|
Fluid Therapy | 1 | 2023 | 593 | 0.040 |
Why?
|
Female | 8 | 2022 | 380194 | 0.040 |
Why?
|
Morphogenesis | 1 | 2022 | 752 | 0.040 |
Why?
|
Middle Aged | 4 | 2020 | 213383 | 0.040 |
Why?
|
Internship and Residency | 1 | 2018 | 5788 | 0.040 |
Why?
|
Ribonuclease III | 1 | 2020 | 275 | 0.040 |
Why?
|
Cohort Studies | 1 | 2020 | 40561 | 0.040 |
Why?
|
Male | 8 | 2022 | 350118 | 0.040 |
Why?
|
Signal Transduction | 1 | 2020 | 23403 | 0.040 |
Why?
|
Phlebography | 1 | 2018 | 333 | 0.040 |
Why?
|
DEAD-box RNA Helicases | 1 | 2020 | 375 | 0.040 |
Why?
|
Organoids | 1 | 2022 | 701 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2019 | 13695 | 0.030 |
Why?
|
Glucosides | 1 | 2020 | 451 | 0.030 |
Why?
|
Heart Failure | 1 | 2020 | 10900 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2019 | 63114 | 0.030 |
Why?
|
Faculty | 1 | 2019 | 386 | 0.030 |
Why?
|
Microvessels | 1 | 2020 | 544 | 0.030 |
Why?
|
Child | 2 | 2020 | 77709 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2022 | 1613 | 0.030 |
Why?
|
Focus Groups | 1 | 2019 | 1321 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2020 | 15165 | 0.030 |
Why?
|
Immunity | 1 | 2020 | 1012 | 0.030 |
Why?
|
Benzhydryl Compounds | 1 | 2020 | 845 | 0.030 |
Why?
|
Neoplasms | 1 | 2023 | 21683 | 0.030 |
Why?
|
Depression | 1 | 2013 | 7766 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2018 | 2274 | 0.030 |
Why?
|
Device Removal | 1 | 2018 | 656 | 0.030 |
Why?
|
Comorbidity | 2 | 2020 | 10388 | 0.030 |
Why?
|
Schools, Medical | 1 | 2019 | 880 | 0.030 |
Why?
|
Drug Discovery | 1 | 2020 | 1058 | 0.030 |
Why?
|
Receptors, Purinergic P2Y | 1 | 2011 | 25 | 0.030 |
Why?
|
Quality of Life | 1 | 2013 | 12804 | 0.030 |
Why?
|
Viral Load | 1 | 2020 | 3299 | 0.020 |
Why?
|
Mentors | 1 | 2016 | 631 | 0.020 |
Why?
|
New York | 1 | 2013 | 886 | 0.020 |
Why?
|
Adult | 2 | 2020 | 214055 | 0.020 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 625 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2021 | 2958 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2021 | 3589 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8663 | 0.020 |
Why?
|
Gene Expression | 1 | 2020 | 7799 | 0.020 |
Why?
|
Computer Simulation | 1 | 2021 | 6196 | 0.020 |
Why?
|
Serine Endopeptidases | 1 | 2011 | 1072 | 0.020 |
Why?
|
Curriculum | 1 | 2019 | 3605 | 0.020 |
Why?
|
Cytokines | 1 | 2021 | 7322 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2022 | 11483 | 0.020 |
Why?
|
Electron Probe Microanalysis | 1 | 2004 | 33 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2020 | 14557 | 0.020 |
Why?
|
Disease Progression | 1 | 2021 | 13284 | 0.010 |
Why?
|
Societies, Medical | 1 | 2016 | 3743 | 0.010 |
Why?
|
Education, Medical, Graduate | 1 | 2016 | 2291 | 0.010 |
Why?
|
Second Messenger Systems | 1 | 2004 | 206 | 0.010 |
Why?
|
Peptide Hormones | 1 | 2004 | 134 | 0.010 |
Why?
|
Aged | 3 | 2022 | 163280 | 0.010 |
Why?
|
Age Factors | 1 | 2020 | 18370 | 0.010 |
Why?
|
Phenotype | 1 | 2021 | 16365 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15540 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 21827 | 0.010 |
Why?
|
Patch-Clamp Techniques | 1 | 2004 | 964 | 0.010 |
Why?
|
Membrane Potentials | 1 | 2004 | 1137 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2020 | 18029 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2020 | 25625 | 0.010 |
Why?
|
Pilot Projects | 1 | 2013 | 8324 | 0.010 |
Why?
|
United States | 2 | 2019 | 69872 | 0.010 |
Why?
|
Infant | 1 | 2020 | 35136 | 0.010 |
Why?
|
Child, Preschool | 1 | 2020 | 41006 | 0.010 |
Why?
|
Incidence | 1 | 2013 | 20947 | 0.010 |
Why?
|
Young Adult | 1 | 2020 | 56430 | 0.010 |
Why?
|
Adolescent | 1 | 2020 | 85781 | 0.010 |
Why?
|
Models, Biological | 1 | 2004 | 9583 | 0.000 |
Why?
|
Risk Factors | 1 | 2013 | 72290 | 0.000 |
Why?
|